A recent study identified four recurring themes related to organizational barriers to quality lung cancer care in a community hospital setting.
What is the average cost per patient for additional therapy or adverse events after CAR-T therapy administration?
Ray D Page, DO, PhD, addresses how including drug costs in bundled payments places oncology practices at the uncontrollable probabilistic risk of patient case mixes.
The United States Preventive Services Task Force released a statement that prostate-specific antigen-based screening for prostate cancer should be avoided in men aged 70 years and older.
Stopping tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia who have achieved deep molecular response could help reduce health expenditure.
Sowmya Josyula, MD, MPH, and Bobby Daly, MD, MBA, discuss the most commonly recognized administrative barriers faced by physicians using oncology clinical pathways and argue that addressing these burdens is crucial in ensuring provider adoption and seamless patient care.
The National Comprehensive Cancer Network has released new guidelines for screening follow-up, ultrasound findings, and other breast cancer considerations.
Older age, African American race, and low socioeconomic status may be linked with a reduced likelihood of receiving multiple myeloma treatment of any kind.
Bijal Shah-Manek, BPharm, PhD, discusses oncologist perceptions of drug affordability and ways to improve existing value frameworks.
For patients with cancer or multiple serious comorbidities, consulting with a palliative care team within 3 days of hospital admission may significantly reduce hospital costs.